Biogen sees no need for big changes in wake of Alzheimer’s drug setback

Biogen (BIIB) is going to buy back more of its own stock.

Any investor hoping for a more radical adjustment to the biotech’s strategic plan following the aducanumab failure — the Alzheimer’s drug setback triggered a $20 billion loss in market value — has to be disappointed.

On a conference call Wednesday following the announcement of first-quarter earnings, Biogen executives expressed some remorse over the early termination of the aducanumab clinical trials. “We followed the science,” said CEO Michel Vounatsos.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In